286 related articles for article (PubMed ID: 3471823)
1. Interaction of aclarubicin with DNA as compared with daunorubicin and doxorubicin.
Ando S; Sasada M; Uchino H; Kagawa D; Ueda T; Nakamura T
Nihon Gan Chiryo Gakkai Shi; 1986 Dec; 21(10):2343-55. PubMed ID: 3471823
[No Abstract] [Full Text] [Related]
2. Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Comparison with daunorubicin and doxorubicin.
Zenebergh A; Baurain R; Trouet A
Cancer Chemother Pharmacol; 1982; 8(2):243-9. PubMed ID: 6955072
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic aspects of aclarubicin with special reference to daunorubicin and doxorubicin.
Skovsgaard T
Eur J Haematol Suppl; 1987; 47():7-20. PubMed ID: 3552720
[No Abstract] [Full Text] [Related]
4. Cytofluorescence localization of anthracycline antibiotics.
Egorin MJ; Clawson RE; Cohen JL; Ross LA; Bachur NR
Cancer Res; 1980 Dec; 40(12):4669-76. PubMed ID: 6934029
[No Abstract] [Full Text] [Related]
5. DNA-binding characteristics of aclarubicin as compared with daunorubicin and doxorubicin.
Ando S; Kamiya K; Yoshimura T; Tsutani H; Ueda T; Uchida M; Nakamura T; Uchino H
Anticancer Res; 1988; 8(3):409-15. PubMed ID: 3164610
[TBL] [Abstract][Full Text] [Related]
6. [New anthracycline antibiotics and derivatives].
Tatsuta K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2640-52. PubMed ID: 6594977
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia.
Meriwether WD; Bachur NR
Cancer Res; 1972 Jun; 32(6):1137-42. PubMed ID: 5030814
[No Abstract] [Full Text] [Related]
8. Cellular accumulation and disposition of aclacinomycin A.
Egorin MJ; Clawson RE; Ross LA; Schlossberger NM; Bachur NR
Cancer Res; 1979 Nov; 39(11):4396-400. PubMed ID: 498071
[TBL] [Abstract][Full Text] [Related]
9. Recent studies on antibiotics and small molecular immunomodulators with potential usefulness in treating lung cancer: Part I - Antitumor antibiotics and their derivatives.
Umezawa H
Int J Clin Pharmacol Ther Toxicol; 1982 Jan; 20(1):12-8. PubMed ID: 6173340
[TBL] [Abstract][Full Text] [Related]
10. The anthracycline antineoplastic drugs.
Young RC; Ozols RF; Myers CE
N Engl J Med; 1981 Jul; 305(3):139-53. PubMed ID: 7017406
[No Abstract] [Full Text] [Related]
11. Experimental studies of new anthracyclines: aclacinomycin, THP-adriamycin and ditrisarubicins.
Umezawa K; Kunimoto S; Takeuchi T
Biomed Pharmacother; 1987; 41(5):206-13. PubMed ID: 2444279
[TBL] [Abstract][Full Text] [Related]
12. In vitro studies on anthracycline haloderivatives.
Facchinetti T; Geroni C; Fumagalli A; Giuliani FC
Drugs Exp Clin Res; 1986; 12(8):657-61. PubMed ID: 3463498
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
[TBL] [Abstract][Full Text] [Related]
14. Anthracycline antibiotic pharmacology and metabolism.
Bachur NR
Cancer Treat Rep; 1979 May; 63(5):817-20. PubMed ID: 455323
[TBL] [Abstract][Full Text] [Related]
15. [Effects of aclacinomycin B on biological macromolecular contents and synthesis of L1210 cells].
Li ZR; Feng JB; Liang F; Zeng SX; Han R
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1984 Jun; 6(3):174-8. PubMed ID: 6241042
[No Abstract] [Full Text] [Related]
16. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
Young CW; Raymond V
Cancer Treat Rep; 1986 Jan; 70(1):51-63. PubMed ID: 2935251
[No Abstract] [Full Text] [Related]
17. Comparative flavoprotein catalysis of anthracycline antibiotic. Reductive cleavage and oxygen consumption.
Pan SS; Pedersen L; Bachur NR
Mol Pharmacol; 1981 Jan; 19(1):184-6. PubMed ID: 6937729
[No Abstract] [Full Text] [Related]
18. Cellular pharmacology of detorubicin and doxorubicin in L1210 cells.
Zenebergh A; Baurain R; Trouet A
Eur J Cancer Clin Oncol; 1984 Jan; 20(1):115-21. PubMed ID: 6537910
[TBL] [Abstract][Full Text] [Related]
19. Biologic properties of three anthracyclines as a function of lipophilicity.
Kessel D
Biochem Pharmacol; 1979 Oct; 28(19):3028-30. PubMed ID: 518699
[No Abstract] [Full Text] [Related]
20. Failure of aclacinomycin and 7-con-O-methylnogarol (7-OMEN) to decrease cardiac guanylate cyclase activity.
Levey BA; Ruiz E; Rogerson B; Lehotay DC; Levey GS
Cancer Treat Rep; 1980; 64(10-11):1127-8. PubMed ID: 6109566
[No Abstract] [Full Text] [Related]
[Next] [New Search]
